The Drug-Dosing Conundrum in Oncology - When Less Is More

N Engl J Med. 2021 Oct 14;385(16):1445-1447. doi: 10.1056/NEJMp2109826. Epub 2021 Oct 9.

Authors

Mirat Shah¹, Atiqur Rahman¹, Marc R Theoret¹, Richard Pazdur¹

Affiliation

¹ From the Office of Oncologic Diseases (M.S.) and the Division of Cancer Pharmacology II, Office of Clinical Pharmacology (A.R.), Center for Drug Evaluation and Research, and the Oncology Center of Excellence (M.R.T., R.P.), Food and Drug Administration, Silver Spring, MD.

PMID: 34623789
DOI: 10.1056/NEJMp2109826

No abstract available

MeSH terms

Antineoplastic Agents / administration & dosage*
Clinical Trials as Topic*
Dose-Response Relationship, Drug
Drug Approval*
Humans
Medical Oncology
Neoplasms / drug therapy*
United States
United States Food and Drug Administration

Substances

Antineoplastic Agents